Market Information
Europe

The Biotechnology Market
in Austria

June 2002

© Department of Foreign Affairs and International Trade
Faxlink # 42588

Report prepared by the Market Research Centre
Market Support Division (TCM)
Department of Foreign Affairs and International Trade
125 Sussex Drive, Ottawa K1A 0G2
Fax: (613) 943-1103
E-mail: mrc@dfait-maeci.gc.ca

The Market Research Centre produces a wide range of market reports by region and sector for Canadian exporters. These reports are available from:
- DFAIT's InfoExport Internet site (http://www.infoexport.gc.ca).

The Government of Canada has prepared this report based on primary and secondary sources of information. Readers should take note that the Government of Canada does not guarantee the accuracy of any of the information contained in this report, nor does it necessarily endorse the organizations listed herein. Readers should independently verify the accuracy and reliability of the information.

Quick Facts

Market Highlights 

• Austria has a strong international reputation for quality biomedical research and development. The country has a strong academic tradition, highly trained researchers, a top-quality education system and well support technology infrastructure.
• There are approximately 75 biotechnology companies active in Austria, the majority of which work in the field of biomedicine and human therapeutics.
• The biotechnology industry in Austria is clustered around Vienna with a large number of academic institutions, scientific associations, research groups, small companies and an increasing number of international firms established in the city.

Opportunities 

• Joint ventures and strategic partnerships in research and development are widely available in Austria.

Key Players 

• Major multinational pharmaceutical and biotechnology corporations are active in the market and the remaining companies are small or medium sized.

Export Checklist 

• As a member of the European Union, biotechnology drugs and human health products must be approved by the European Medicines Evaluation Agency Austria is also bound by the EU's external tariff system and common agricultural policy.
• The Austrian reimbursement system for pharmaceuticals has been criticized for being nontransparent and arbitrary and action to relieve the situation is currently before the European Court of Justice. A decision is expected by mid-2002.

Market Summary

• Austria offers an excellent location from which to access biotechnology markets in both Western and Eastern Europe. The European market for biotechnology goods and services has been estimated at $68 billion¹ and is forecast to exceed $228 billion by 2005. According to the European Federation of Biotechnology, there are 1570 biotechnology companies in Europe and over 1000 research institutions.
• Austria has a strong international reputation for quality biomedical research and development. The country has a strong academic tradition, highly trained researchers, a top-quality education system and well support technology infrastructure. In fact, a study by the European Molecular Biology Organization (EMBO) concluded that Austria is among the ten leading nations worldwide, and a leading nation in Europe, in the areas of biology and biochemistry. These sectors are critical to support growth in the biotechnology industry.
• Key biotechnology areas in Austria include medical biotechnology, industrial applications of biotechnology, environmental biotechnology, and to a lesser extent, agricultural biotechnology. There is particular expertise in Austria in cancer research, and immunology.
• There are approximately 75 biotechnology companies active in Austria, the majority of which work in the field of biomedicine and human therapeutics. Major multinational pharmaceutical and biotechnology corporations are active in the market and the remaining companies are small or medium sized. Beyond the core biotechnology industry, there are also a series of companies which offer support services to the biotechnology industry, including equipment suppliers, law offices and traditional pharmaceutical companies.
• The pharmaceutical industry in Austria was valued at $5 billion in 2001 with approximately $2.3 billion in exports. There are an estimated 230 pharmaceutical manufacturers in Austria, less than half of which account for 95% of all domestic sales. The Austrian market for medical biotechnology products was estimated at $2.4 billion in 2000.
• In 2000, total production of biopharmaceuticals in Austria totaled $1.6 billion, the majority of which was exported. Major multinational biotechnology companies including Baxter AG, Novartis, Eli Lilly and Boehringer Ingelheim have manufacturing facilities in Austria and export products throughout Europe and North America.
• There are smaller clusters of biotechnology activity in Graz, Innsbruck, Krems and Salzburg focused primarily around research centres at local universities.
• There is limited work on stem cell research in Austria, primarily because of ethical and moral objections to research involving embryonic stem cells. In fact, the government has responded to public concerns and banned embryonic stem cell research outright. Manipulating embryos is only permitted in an effort to ensure pregnancy.
• In response to public concerns related to biotechnology, the Austrian government established the Commission for Gene Technology, an advisory body of representatives from various backgrounds. The commission is tasked with advising the chancellor on genetics and bio-ethics and initiating public debate in Austria.
• As is the case in much of Europe, the Austrian public remains suspicious of agricultural biotechnology. Consumers appear willing to pay 10-15% more for organic products, which now accounts for an estimated 10% of the retail food market. The Austrian government has also strongly opposed any actions taken by the European Union to approve genetically modified food products.
• In January 2002 the Austrian Minister of Agriculture² announced that effective immediately grain producers must certify that their products are free of GMOs, within a tolerance of 0.1%. This applies to both conventional and organic seed. This strict tolerance has been greeted with criticism from the grain industry and is considered both unworkable and cost prohibitive. Its impact remains to be seen, both domestically and for foreign seed and grain exporters.

Government Support for Biotechnology

• Biotechnology and other research sectors receive strong support from the Austrian government. The Green Paper on Austrian Research Policy articulates the importance of a strong research foundation for the Austrian economy and confirms government commitment to research excellence and collaboration.
• The Austrian government is committed to increasing the share of GNP dedicated to research and development in all sectors from 2% to 2.5% by 2005. As part of  this innovation policy to increase competitiveness, directed by the Ministry for Education, Science and Culture, the government is looking to network with European partners and build on domestic capabilities. The strategy of theme based research programs will include an emphasis on biotechnology and genetic engineering. Direct funding for biotechnology projects is offered through the Austrian Science Fund.
• The Bureau for International Research and Technology Cooperation (BIT) is a joint initiative of the Austrian government and the Austrian Federal Economic Chamber in collaboration with Austrian science-based organizations. BIT's primary role is to serve as a national information service centre for global information pertaining to life sciences, including all European Union funding initiatives, and to ensure Austrian participation in the industry internationally. Additional details may be found on the bureau's website at: http://www.bit.ac.at.
• The Austrian government established the Technologie Impulse Gesellschaft (TIG) to serve as an implementation body and program manager for technology based programs. These programs include:
• K-Plus Competence Centres. This program is designed to stimulate cooperation between research centres and private companies. Based on existing infrastructure, K-Plus supports internationally competitive research by establishing and supporting a core competence centre. In the field of biotechnology, the Bio-Molecular Therapeutics (BMT) centre brings together 4 scientific groups from the University of Vienna and the University of Agricultural Sciences as well as 6 corporate partners and additional support from the city of Vienna. The aim of BMT is to identify novel molecules and develop diagnostic and therapeutic strategies for a variety of disease areas.
• The A Plus B program began in 2001 and is designed to support spin-off companies from Austrian universities. A Plus B provides a team of experts to help scientists and researchers move from a pure research base environment to an entrepreneurial business environment.
• The enormously successful Impulse Program Biotechnology (Impulseprogramm Biotechnologie) has recently been replaced by LISA - Life Sciences Austria, administered by the government's Innovation Agency. LISA will continue the work of the Impulse Program by helping scientists establish their own companies, but will further assist in biotechnology growth by sponsoring business plan competitions, assisting with identification of valuable ideas, offering scientists business training and providing some financial assistance for patent applications and start-up costs. LISA has also partnered with BIT to offer faster access to European Union programs and with the City of Vienna's Centre for Innovation to offer location services and additional regional funding to start-up companies.
• To support growth and development in genomic research and technology transfer, the government has recently announced the creation of GEN-AU, a national genome program with $43 million allocated over 3 years. GEN-AU is designed to increase Austria's competitiveness and to encourage growth and job creation in genomics and biotechnology research.

Key Research Centres

• There are 12 universities and 3 medical schools in Austria conducting research into various applications of biotechnology. A complete list of schools and their various research centres is available at: http://www.bit.ac.at/4_fue_5rp_1tp_ba_uni.htm.
• The University of Agricultural Sciences (BOKU) in Vienna includes a series of institutes and research centres all devoted to specific agricultural research areas. Important centres of biotechnology research include
• The Institute for Applied Microbiology which uses good manufacturing practices (GMP) to produce biopharmaceuticals for clinical trials using fermentation strategies with microorganisms and mammalian cell cultures.
• The Institute for Agrobiotechnology in Tulln focuses on animal, plant and environmental biotechnology applications. The institute conducts interdisciplinary research on innovative production techniques, molecular genetics, and biopolymers.
• The Centre for Applied Genetics (ZAG) is focused on molecular cell biology, plant and microbe interaction and plant based molecular biotechnology.
• In partnership with the Institute for Biochemistry at the University of Innsbruck and corporate partners, BOKU has established the Austrian Centre for Biopharmaceutical Technology (ACBT). The centre develops biopharmaceutical processing technology based on innovative engineering and biotechnology principles.
• The University of Vienna is a focal point for biotechnology research and development in Austria. In collaboration with BOKU, the university is looking into creating a life sciences university. Basic and applied research is focused within the Faculty of Medicine and the Faculty for Natural Sciences and Mathematics. Key research centres include the Institute of Immunology, the Institute of Cancer Research, the Institute of Biomedical Research, the Department of Biomedical Engineering and Physics, and the Institute of Pharmaceutical Technology and Biopharmaceuticals.
• The University of Innsbruck also has a focus on biotechnology and bio-sciences research through various institutes within the Faculty of Medicine and the Faculty of Science. The Tyrolean Cancer Research Institute and the Austrian Academy of Science Institute for Biomedical Aging Research are also located at the university.
• The Tyrolean Cancer Research Institute is largely a privately funded research centre (some EU and scientific foundation funding) dedicated to cancer research with a direct clinical impact.
• The Austrian Academy of Science supports research outside the university system in Austria and includes all areas of scientific inquiry. Important institutes of biotechnology research include the Institute for Biomedical Aging Research, Institute for Molecular Biology, the Centre of Molecular Medicine, and the Institute of Molecular and Cellular Bioinformatics (in cooperation with Boehringer Ingelheim and VBC). The academy recently recruited Austrian born Canadian scientist Josef Penninger, a specialist in genetic research.
• Boehringer Ingelheim's investment in a cancer research centre, the Institute of Molecular Pathology (IMP), in Vienna (see below) prompted additional cooperation between the company, the Vienna Bio-Center and the Austrian Academy of Sciences to establish the Institute of Molecular and Cellular Bioinformatics (IMBA) within VBC. The institute will focus on functional genomics with applications for heart disease and cancer.
• Biochemie and their partner Novartis have opened an Antibiotic Research Institute in Vienna as a basic research facility focused on antibacterial research. The institute has an annual budget of approximately $9.5 million and is located next to the Novartis Research Institute.
• Baxter has contributed to the growth of privately funded research centres with the creation of the Bioscience's Global Pathogen Safety Centre of Excellence in Vienna.

Opportunities

• The Austrian government's commitment to increased research and development spending will provide additional funding for both domestic research programs and international collaboration. As a result, Canadian biotechnology companies may find opportunities to partner with Austrian companies or research institutes.
• Joint ventures and strategic partnerships in research and development are widely available in Austria. The Bureau for International Research and Technology Cooperation and Canadian trade commissioners in Austria are good starting points to research potential partners.

Key Players

• Austria has attracted biotechnology investment from major industry players in both Europe and North America. For example, Baxter AG (US), Novartis (Swiss), Octapharma AG (Swiss), and Eli Lilly (US) all have research and production facilities in Austria. In fact, multinational biotechnology and pharmaceutical companies employ more than 10,000 people in Austria.
• Baxter AG Oesterreich is the largest biopharmaceutical manufacturer in Austria with sales of more than $3 billion annually. The company produces a vaccine to prevent Lyme disease, small pox vaccines, hemophilia treatments, a recombinant hemoglobin solution as a blood substitute for trauma victims, and operates a subsidiary researching xeno-transplantation.
• In December 2001 Boehringer Ingelheim announced an $84 million investment in biotechnology in Vienna. The pharmaceutical giant will expand its Institute of Molecular Pathology and protein production facility in 2002 and increase research funding in other disease areas.
• Biochemie Kundl, a subsidiary of Novartis AG operates a production facility specializing in vaccines and antibiotics and will invest $150 million in two new production facilities in 2002. The company has expertise in microbial fermentation of classic and recombinant micro-organisms and exports pharmaceutical ingredients.
• Oridis Biomed is a small start-up located in Graz. The company was the winner of the Best of Biotech (BOB) business plan competition sponsored by the Innovation Agency in 2001. The company is focused on identifying drug targets for liver cancer treatment, based on their exclusive access to the world's largest tissue bank at the City Hospital of Graz.
• Innovacell is new start-up company in Innsbruck established with government financing and focused on incontinence treatment.
• Intercell Biomedical Research & Development AG is the first spin-off company from the Vienna BioCentre. The company develops vaccines for cancer and infectious diseases and has been enormously successful in attracting venture capital investments.
• Igeneon currently holds the record among biotechnology companies in Austria for securing the largest amount of venture financing. The company raised almost $40 million in late 2001. Igeneon develops cancer therapies and treatments and will use the money to fund clinical testing for vaccine products.

Export Checklist

• While German is Austria's official language, English is the second most widely used language in business and most Austrians can communicate with English speaking colleagues. Nevertheless, German should be used in all contracts and related documentation to minimize any potential confusion.
• Canadian companies will find that there are no major foreign exchange restrictions in Austria and payment transactions can be conducted with relative ease.
• Tensions between right wing political forces in Austria and critics in the European Union have caused a certain amount of isolation for Austria in recent years. Economically, however, the nation continues to pursue opportunities resulting from closer integration with other member states in the Union.
• Canadian firms may wish to seek the assistance of an experienced agent who is familiar with both Austrian and European Union procedures relating to biotechnology products and services.

Medical Biotechnology

• The European Medicines Evaluation Agency (EMEA) is responsible for the administration of common rules relating to the approval, quality and safety of prescription drugs, including all biotechnology-derived products, in the European Union, as well as monitoring compliance with the guidelines. The EMEA's endorsement of a new drug is binding in all EU member states. The application and approval process takes between 300 and 500 days, and costs approximately $250,000.
• Pharmaceuticals that cannot be registered through the EMEA-including established (non-innovative drugs) and products requiring re-registration due to changes in format or packaging-follow national procedures. The national body responsible for drug approvals and monitoring in Austria is the Federal Ministry for Health and Social Affairs.
• The Austrian reimbursement system for pharmaceuticals has been criticized for being non-transparent and arbitrary and action to relieve the situation is currently before the European Court of Justice. A decision is expected by mid-2002.

Agricultural Biotechnology

• As a member of the European Union, Austria is bound by the EU's external tariff system and common agricultural policy.
• Prior to the 1998 moratorium on approvals of genetically modified food products, the European Union had approved 18 GM products for sale and a further 14 were awaiting approval.
• On January 21, 2002, the European Union established the European Food Safety Authority (EFSA) as well as a new framework for EU food law. The regulation sets out guiding principles for the traceability of all foodstuffs, animal feed and food ingredients, including all genetically modified organisms from the shelf in the store straight back to the farm or the field. The regulation also places responsibility for food safety on companies who put items on the market and includes procedures for developing food law and dealing with food emergencies.
• The European Commission has also determined that once the moratorium on genetically modified food approvals is lifted (perhaps by mid-to-late 2002), strict labeling requirements will be put into place to ensure consumers know which foods contain modified products and which do not. The labeling regulations will include a 1% tolerance level.

Key Contacts

Canadian Government Contacts

Canadian Embassy in Austria
Laurenzerberg 2
A-1010 Vienna, Austria
Tel.: (43-1) 531-38-3355
Fax: (43-1) 531-38-3906
Contact: Nickolaus Hottenroth, Business
Development Officer
E-mail: vienn-td@dfait-maeci.gc.ca
Internet: http://www.kanada.at

Agriculture and Agri-Food Canada
Market and Industry Services Branch
Sir John Carling Building
930 Carling Ave.
Ottawa, ON K1A 0C5
Tel.: (613) 759-7744
Fax: (613) 759-7499
Internet: http://www.agr.gc.ca

Canadian Food Inspection Agency
Office of Biotechnology
59 Camelot Dr.
Nepean, ON K1A 0Y9
Tel.: (613) 225-2342
Fax: (613) 228-6653
E-mail: cfiamaster@agr.gc.ca
Internet: http://www.inspection.gc.ca

Export Development Canada (EDC)
151 O'Connor St.
Ottawa, ON K1A 1K3
Tel.: 1-888-332-3320 or (613) 598-2500
Fax: (613) 237-2690
E-mail: export@edc-see.ca
Internet: http://www.edc-see.ca

Health Canada
International Affairs Directorate
Brooke Claxton Building, Room 814A
Postal Locator 0908A
Tunney's Pasture
Ottawa, ON K1A 0K9
Tel.: (613) 941-3136
Fax: (613) 952-7417
Internet: http://www.hc-sc.gc.ca

Department of Foreign Affairs and International Trade (DFAIT)
125 Sussex Dr.
Ottawa, ON K1A 0G2
Internet: http://www.dfait-maeci.gc.ca

Market Research Centre (TCM)
Tel.: (613) 996-3535
Fax: (613) 943-1103
Contact: Michelle Van Dyk, International Market Research Officer
E-mail: michelle.van-dyk@dfait-maeci.gc.ca
Internet: http://www.infoexport.gc.ca

Market Support Division (TCM)
Tel.: (613) 996-1431
Fax: (613) 944-0050
Contact: Patricia Filteau, Trade Commissioner
E-mail: patricia.filteau@dfait-maeci.gc.ca
Internet: http://www.infoexport.gc.ca
Northern Europe Division (REN)
Tel.: (613) 943-0893
Fax: (613) 995-6319
Contact: Yvonne Gruenthaler, Desk Officer
E-mail:
yvonne.gruenthaler@dfait-maeci.gc.ca

Industry Canada
Life Sciences Branch
PO Box 940, Station M
1505 Barrington St.
Halifax, NS B3J 2V9
Tel.: (902) 426-9958
Fax: (902) 426-2624
Contact: Mark Craig, Sector Officer
E-mail: craig.mark@ic.gc.ca
Internet: http://strategis.ic.gc.ca

Canadian Industry Associations

Ag-West Biotech
101 - 111 Research Dr.
Saskatoon, SK S7N 3R2
Tel.: (306) 975-1939
Fax: (306) 975-1966
E-mail: agwest@agwest.sk.ca
Internet: http://www.agwest.sk.ca

Alberta Biotechnology Association
1150, 10180 - 101 St.
Edmonton, AB T5J 3S4
Tel.: (780) 425-3815
Fax: (780) 423-3893
Contact: Myka Osinchuk, Executive Director
E-mail: myka@bioalberta.com
Internet: http://www.bioalberta.com

BioAtlantech
PO Box 636, Station A
Fredericton, NB E3B 5A6
Tel.: (506) 444-2444
Fax: (506) 444-5662
Internet: http://www.bioatlantech.nb.ca

BioEast
2 nd Floor, Spencer Hall
220 Prince Philip Dr.
St. John's, NF A1B 3X5
Tel.: (709) 737-2682
Fax: (709) 737-4029
Contact: Margaret Miller, Managing Director
Internet: http://www.bioeast.ca

BIONova
c/o Innovacorp
101 Research Dr.
PO Box 790
Dartmouth, NS B2Y 3Z7
Tel.: (902) 424-8670
Fax: (902) 424-4679
Internet: http://www.bionova.ns.ca

Bio Quebec
6100 Avenue Royalmount
Montreal, QC H4P 2R2
Tel.: (514) 733-8411
Fax: (514) 733-8272
E-mail: info@bioquebec.com
Internet: http://www.bioquebec.com

BIOTECanada
130 Albert St., Suite 420
Ottawa, ON K1P 5G2
Tel.: (613) 230-5585
Fax: (613) 563-8850
E-mail: info@biotech.ca
Internet: http://www.biotech.ca

British Columbia Biotechnology Alliance
3250 East Mall, Suite 225
Vancouver, BC V6T 1W5
Tel.: (604) 221-3020
Fax: (604) 221-3027
Contact: Paul Stinson, Executive Director
Internet: http://www.bcbiotech.ca

Canadian Agri-Food Research Council
Building 60, Heritage House
Central Experimental Farm
Ottawa, ON K1A 0C6
Tel.: (613) 234-2325
Fax: (613) 234-2330
Internet: http://www.carc-crac.ca

Canada's Research-Based Pharmaceutical Companies
302-1111 Prince of Wales Dr.
Ottawa, ON K2C 3T2
Tel.: (613) 727-1380
Fax: (613) 727-1407
Internet: http://www.canadapharma.org

Ottawa Life Sciences Council
600 Peter Morand Dr., Suite 100
Ottawa, ON K1G 5Z3
Tel.: (613) 521-1008
Fax: (613) 521-3065
Internet: http://olsc.ca

Toronto Biotechnology Initiative
PO Box 446, Station A
Toronto, ON M5W 1C2
Tel.: (416) 392-4780
Fax: (416) 397-0906
Internet: http://www.torontobiotech.org

European Government and Industry Contacts

EuropaBio
Avenue de l'Armée 6
1040 Brussels, Belgium
Tel.: (32-2) 735-0313
Fax: (32-2) 735-4960
E-mail: mail@europabio.org
Internet: http://www.europabio.org

European Agency for the Evaluation of Medicinal Products (EMEA)
7 West Ferry Circus
Canary Wharf
London, UK E14 4HB
Tel.: (44-171) 418-8400
Fax: (44-171) 418-8416
E-mail:mail@emea.eudra.org
Internet: http://www.emea.eu.int

European Diagnostics Manufacturers Association (EDMA)
Place St. Lambert 14
1200 Brussels, Belgium
Tel.: (32-2) 772-2225
Fax: (32-2) 772-2329
E-mail: edma@edma-ivd.be
Internet: http://www.edma-ivd.be

European Food Safety Authority (EFSA)
Temporarily located within the European Commission in,
Brussels, Belgium
Internet: http://www.efsa.eu.int

European Federation of Pharmaceutical Industries Association (EFPIA)
250 Ave. Louise
Box 91
B 1050 Brussels, Belgium
Tel.: (32-2) 640-6815
Fax: (32-2) 647-6049
Internet: http://www.efpia.org

European Generic Medicines Association
PO Box 193
B-1040 Brussels 4, Belgium
Tel.: (32-2) 736-8411
Fax: (32-2) 736-7438
Internet: http://www.egagenerics.com

European Patent Office
Erhardtstrasse 27
D80331 Munich, Germany
Tel.: (49-89) 239-90
Fax: (49-89) 239-94-465
Internet: http://www.european-patentoffice.
org/index.htm

Office for Harmonization in the Internal Market
(Trade Marks and Designs)
Av. Aguilera 20
03080 Alicante, Spain
Tel.: (346) 513-9100
Fax: (346) 513-9179
Internet: http://oami.eu.int

Austrian Government Contacts

Austrian Business Agency
Openring 3
A-1010 Vienna, Austria
Tel.: (43-1) 588-58-0
Fax: (43-1) 586-8659
Internet: http://www.aba.gv.at

Austrian Trade Commission
2 Bloor Street West, Suite 400
Toronto, ON M4W 3E2
Tel.: (416) 967-3348
Fax: (416) 967-4101
E-mail: toronto@wko.at
Internet: http://www.austriantradeus.org

(Canadian site under construction)

Quebec
1010 Sherbrooke St. W, Suite 1410
Montreal, QC H3A 2R7
Tel.: (514) 849-3708
Fax: (514) 849-9577
E-mail: montreal@wko.at

Federal Ministry of Agriculture, Forestry, Environment and Water Management (Bundesministerium für Land- und Forstwirtschaft, Umwelt und Wasserwirtschaft in Österreich - BMLFUW)
Stubenring 1
A-1012 Vienna, Austria
Tel.: (43-1) 7110-06776
Fax: (43-1) 7110-02142
Internet: http://www.lebensministerium.at/en/

Federal Ministry for Economic Affairs and Labour (Bundesministerium für Wirtschasft und Arbeit - BMWA)
Stubenring 1
A-1010 Vienna, Austria
Tel.: (43-1) 711-00-0
Fax: (43-1) 713-7995
Internet: http://www.bmwa.gv.at

Federal Ministry for Education, Science and Culture (Bundesministerium für Bildung, Wissenschaft und Kultur - BMBWK)
Minoritenplatz 5
A-1014 Vienna, Austria
Tel.: (43-1) 53-120-0
Fax: (43-1) 53-120-3099
Internet: http://www.bmbwk.gv.at

Federal Ministry for Health and Social Affairs (Bundesministerium für soziale Sicherheit und Generationen - BMSG)
Stubenring 1
A-1010 Vienna, Austria
Tel.: (43-1) 711-00-0
Internet: http://www.bmsg.gv.at (German only)

Federal Ministry of Transport, Innovation and Technology (Bundesministerium für Verkehr, Innovation und Technologie - BMVIT)
Radetzkystrasse 2
A-1030 Vienna, Austria
Tel.: (43-1) 711-62-0
Internet: http://www.bmv.gv.at

Life Science Austria (LISA) Innovation Agency (Innovationsagentur)
Taborstr. 10
A-1020 Vienna, Austria
Tel.: (43-1) 216-5293-346
Fax: (43-1) 216-5293-99
Contact: Dr. Sonja Hammerschmid
Email: office@lifescienceaustria.at
Internet: http://www.lifescienceaustria.at

Technologie Impulse Gesellschaft (TIG)
Grillparzerstraße 7A-1010 Vienna, Austria
Tel.: (43-1) 513-2627-0
Fax: (43-1) 513-2627-10
E-mail: office@tig.or.at
Internet: http://www.tig.or.at
Note: German introduction page, but each of the three programs from the menu have English pages.

Austrian Research Contacts and Associations

Austrian Academy of Sciences
Dr. Ignaz Seipel-Platz 2
A-1010 Vienna, Austria
Tel.: (43-1) 51581-0
Internet: 
http://www.oeaw.ac.at/english/home.html

Austria - Canada Business Club
Magna-Strasse 1
2522 Oberwaltersdorf, Austria
Tel.: (43-225) 3200-2220
Fax: (43-225) 3200-2240
E-mail: office@acbc.at
Internet: http://www.acbc.at

Austrian Society for Biotechnology 
(Österreichische Gesellschaft für Biotechnologie - ÖGBT)
Dr. Boehringer-Gasse 5-11
A-1121 Vienna, Austria
Tel.: (43-1) 80-105-2311
Fax: (43-1) 80-105-9311
Internet: http://www.boku.ac.at/oegbt (mostly German)

Austrian Research Centers
A-2444 Seibersdorf, Austria
Tel.: (43) 505 50-0
Fax: (43) 2254-7406-0
E-mail: seibersdorf@arcs.ac.at
Internet: http://www.arcs.ac.at

Bureau for International Research and Technology Cooperation ( Büro für Internationale Forschungs - und Technologiekooperation - BIT)
Donau-City-Str.1
A-1220 Vienna, Austria
Tel.: (43-1) 581-1616
Fax: (43-1) 581-1616 -16
Contact: Dr. DI Sabine Herlitschka, Deputy Director
E-mail: bit@bit.ac.at
Internet: http://www.bit.ac.at

IMP (Institute of Molecular Pathology)
Dr. Bohr Gasse 7
A-1030 Vienna, Austria
Internet: http://www.imp.univie.ac.at

Pharmig - Pharmaceutical Companies' Association of Austria
Zieglergasse 5 (Postfach 94)
A-1072 Vienna, Austria
Tel.: (43-1) 523-2951-0
Fax: (43-1) 523-2951-9
E-mail: office@pharmig.at
Internet: http://www.pharmig.or.at

University of Agricultural Sciences
(Universität für Bodenkultur - BOKU)
Gregor Mendel Str. 33
A-1180 Vienna, Austria
Tel.: (43-1) 476-54-0
Internet: http://www.boku.ac.at

University of Innsbruck
Christoph-Probst-Platz
Innrain 52
A-6020 Innsbruck, Austria
Tel.: (43) 512-507-0
Internet: http://info.uibk.ac.at/index-en.html
Note: Includes links to Austrian Pharmacological Society and various institutes within the Faculty of Medicine.

University of Vienna
Dr. Karl Lueger Ring 1
A-1010 Vienna, Austria
Internet: http://www.univie.ac.at
Note: A complete list of research centres and hyperlinks is available at http://www.bit.ac.at/4_fue_
5rp_1tp_ba_uni.htm.

Vienna BioCentre
Dr. Bohr Grasse 9
A-1030 Vienna, Austria
Internet: http://www.at.embnet.org/vbc

References

Abraham, Carolyn. "Star Scientist Decides to Quit Canadian Lab," Globe and Mail, December 2001.

Austria. Federal Ministry for Education, Science and Culture (Bundesministerium für Bildung, Wissenschaft und Kultur). "Declaration of the Federal Government on Current Issues in Research and Technology Policy". Downloaded on January 30, 2002 from http://www.bmbwk.gv.at/start.asp?isIlink=
1&bereich=2&l1=&l2=&l3=&OID=3743#.

----. "Green Paper in Austrian Research Policy." Downloaded on April 8, 2002 from http://www.bmbwk.gv.at/start.asp?isIlink=
1&bereich=2&l1=&l2=&l3=&OID=3747#.

----. "Genome Research in Austria," 2001. Downloaded on April 8, 2002 from http://www.bmbwk.gv.at/start.asp?isIlink=
1&bereich=2&l1=&l2=&l3=&OID=3460# 

Austria. Bureau for International Research and Technology Cooperation. "Austrian Biotechnology Company Directory," 2001. Available online at: http://www.bit.ac.at/BioAustria1.htm.

----. "Life Sciences, Research and Technology in Austria," 2001. Downloaded on January 30, 2002 from http://www.bit.ac.at/BioAustria1.htm.

Austrian Business Monitor. "Boehringer Ingelheim Invests in Biotech," December 2001.

Austrian News Digest. "Austrian Prisma to Build Biotechnological Research Centre in Innsbruck," March 2002.

----. "Austrian Biochemie to Invest 109.1mln Euros in Production Facilities in 2002," December 2001.

----. "Austrian Biotechnology Sector to Generate 1.6 bln Euro Value Added by 2015, BCG says," November 2001.

Bonn, Guenther. "Life Sciences in Austria - From Impulses to Success," Nature, April 2002. Available online at: http://www.nature.com.

Canada. Department of Foreign Affairs and International Trade. "The Biotechnology Sector in Austria - Slow Take-Off, but Finally Booming," 2001. Available online at: http://www.infoexport.gc.ca/main-e.asp?
act=3&nid=564#Europe.

China Post. "Austrian Biotechnology Looks to Taiwan for Opportunities," May 2001.

Die Presse. "Vienna ranks 37th on Global League Table of Biotechnology Firms," November 2001.

----. "Austrian Pharma Industry Faces Structural Changes," April 2001.

----. "Baxter Austria wins U.S. Smallpox Vaccine Contract," November 2001.

Hammerschmid, S., Kuchler, K., and T.C. Jelitto. "Austria - Science Alive," Nature, August 2000. Available online at http://www.nature.com.

Jaffe, Joshua. "Igeneon Draws $26.5M in Second Round," The Daily Deal, August 2001.

Marketletter. "New Antibiotics Basic Research Unit Set up by Novartis Biochemie," November 2001.

Munro, Margaret. "Wide Range of Embryo and Cloning Regimes Emerges," National Post, March 2001.

Pharmazeutishe Industrie. "Baxter Builds New Centre," April 2001.

Reuters News. "Morphosys, Oridis Link Up to Find Drug Targets," September 2001.

United States. United States Department of Commerce. "Austria: Biotechnology for Medical / Pharmaceutical Applications," September 2001.

----. "Austria: Austria as a Major Location for Biotechnology Research and Production," August 2001.

----. "Austria: An Outline of the Pharmaceutical Sector," September 2001.

1 All monetary amounts are expressed in Canadian dollars, unless otherwise indicated. The conversion rate to Canadian dollars is based on IDD Information Services, Tradeline, April 2002.

2 For contact information regarding key organizations mentioned in this report, see Key Contacts.